On November 22, 2021 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, reported that it participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held on November 29-December 2, 2021 (Press release, Cue Biopharma, NOV 22, 2021, View Source [SID1234608266]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pre-recorded presentation will be available to participants during the conference and on the Events page of the Investor & Media section of the Company’s website www.cuebiopharma.com beginning today, November 22, 2021 at 10:00 a.m. EST. An archived version of the recording will be accessible for 90 days following the event.

On November 22, 2021 Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, reported that CEO Masoud Tavazoie, M.D., Ph.D., will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 A.M. EST on November 22, 2021 (Press release, Inspirna, NOV 22, 2021, View Source [SID1234596758]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A pre-recorded webcast of the presentation will be available at the time of the presentation and will be available on Inspirna’s website within the News section.

On November 22, 2021 Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, reported that Chief Executive Officer, Dr. Ian Walters, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021 (Press release, Portage Biotech, NOV 22, 2021, View Source [SID1234595957]). Dr. Walters will give an overview of Portage’s pipeline and status of current programs, including the company’s lead invariant natural killer T cell (iNKT) agonists, PORT-2 and PORT-3.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pre-recorded presentation is available now through the following link (here) as well as on the Investor section of the company’s website at View Source Management will also be hosting 1×1 meetings on November 30 and December 1.

On November 22, 2021 Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, reported that it has signed agreements to acquire Centro Oncológico de Antioquia (COA) and Clínica Clofán, further expanding the company’s presence in Colombia (Press release, Fresenius, NOV 22, 2021, View Source [SID1234595954]). The clinics, located in Colombia’s second largest city Medellín, will become part of Quirónsalud’s existing healthcare network in the country, which already comprises six hospitals and ten diagnostic centers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

COA is specialized in the diagnosis and treatment of cancer. It has 75 beds, four operating rooms, and specialized centers for nuclear medicine, radiotherapy and bone marrow transplants. Clínica Clofán is the second largest ophthalmic center in the city, with ten operating rooms and further dedicated facilities for treating even severe ophthalmic diseases and performing complex procedures.

Both clinics offer state-of-the-art medical standards and technology to their patients and are regarded as leading medical facilities with highly renowned physicians. Together they generate sales of around €30 million.

The acquisition is another important step in strengthening Fresenius Helios’ presence in the growing and consolidating healthcare services markets in Latin America.

The transaction is expected to close in the first quarter of 2022, pending anti-trust clearance of the Colombian authorities. Fresenius Helios expects the acquisition to be accretive to Fresenius’ Group net income already in fiscal year 2022.

On November 22, 2021 Flywheel, the leading cloud-scale informatics platform for biomedical research and collaboration, reported the successful integration of its platform by Roche and Genentech, a member of the Roche Group, for ingestion, classification, standardization, curation and analysis of medical imaging data (Press release, Hoffmann-La Roche, NOV 22, 2021, View Source [SID1234595953]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The secure, scalable Flywheel platform enables aggregation and management of medical imaging and associated data to accelerate drug discovery. The data is organized and processed with automated pipelines—saving significant time and minimizing the potential for human error in the drug development process. Cost and timeline efficiencies allow researchers to focus on what matters most—bringing life-changing therapies to patients faster. Moreover, Flywheel’s unique approach has enabled multi-site collaboration and development of a customized solution for Roche and Genentech’s needs.

"Manual processes to curate data at the terabyte and petabyte levels are historically costly, time-consuming and prone to human error. With our platform in place, Roche and Genentech researchers can access high-quality images for complex analysis and machine learning, ultimately speeding the development of innovative therapies," said Jim Olson, CEO of Flywheel. "Before using the platform, this level of collaboration and analysis was simply not possible."

"At Roche we envision a future where data, analytics and digital technologies routinely enable more targeted, efficient research and development and more integrated, personalized care," said James Sabry, Head of Roche Pharma Partnering. "The Flywheel platform enables rapid access to highly-curated imaging data, enhancing our ability to answer key scientific questions that are critical to advancing better patient care experiences and outcomes."

Life sciences organizations are making significant investments in digital transformations that foster AI technology in hopes of improving R&D processes and bringing drugs to the market faster. Modern infrastructures are needed to aggregate, curate, and analyze a vast assortment of rich, biomedical data to support these initiatives and enable machine learning, big data analytics, and other strategic data-driven objectives.